1 Guidance

1 Guidance

1.1 Aflibercept solution for injection is recommended as an option for treating wet age‑related macular degeneration only if:

  • it is used in accordance with the recommendations for ranibizumab in NICE technology appraisal guidance 155 (re‑issued in May 2012) and

  • the manufacturer provides aflibercept solution for injection with the discount agreed in the patient access scheme.

1.2 People currently receiving aflibercept solution for injection whose disease does not meet the criteria in 1.1 should be able to continue treatment until they and their clinician consider it appropriate to stop.

  • National Institute for Health and Care Excellence (NICE)